{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:53:12Z","timestamp":1786117992841,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1097\/01.inf.0000243211.36690.d5","type":"journal-article","created":{"date-parts":[[2006,10,23]],"date-time":"2006-10-23T05:39:05Z","timestamp":1161581945000},"page":"1049-1056","source":"Crossref","is-referenced-by-count":19,"title":["Diminished Selection for Thymidine-Analog Mutations Associated With the Presence of M184V in Ethiopian Children Infected With HIV Subtype C Receiving Lamivudine-Containing Therapy"],"prefix":"10.1097","volume":"25","author":[{"given":"Diana","family":"Averbuch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Schapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Randall","family":"Lanier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Gradstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giora","family":"Gottesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eynat","family":"Kedem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menachem","family":"Einhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galia","family":"Grisaru-Soen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Ofir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Engelhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehava","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-12-20210202","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00126334-200307010-00007","article-title":"Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection.","volume":"33","author":"Ariyoshi","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R3-12-20210202","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1128\/JVI.76.4.1753-1761.2002","article-title":"Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection.","volume":"76","author":"Brenner","year":"2002","journal-title":"J Virol"},{"key":"R4-12-20210202","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1128\/JCM.39.7.2652-2654.2001","article-title":"Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom.","volume":"39","author":"Cane","year":"2001","journal-title":"J Clin Microbiol"},{"key":"R6-12-20210202","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/00002030-200108170-00001","article-title":"Genotypic variation of HIV-1 reverse transcriptase and protease: Comparative analysis of clade C and clade B.","volume":"15","author":"Grossman","year":"2001","journal-title":"AIDS"},{"issue":"suppl 3","key":"R7-12-20210202","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1097\/00002030-200317003-00006","article-title":"Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative\u2014Uganda.","volume":"17","author":"Weidle","year":"2003","journal-title":"AIDS"},{"key":"R8-12-20210202","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1089\/088922202320935483","article-title":"HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy.","volume":"18","author":"Kantor","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R9-12-20210202","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1371\/journal.pmed.0020112","article-title":"Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration.","volume":"2","author":"Kantor","year":"2005","journal-title":"PLoS Med"},{"key":"R10-12-20210202","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1128\/AAC.48.6.2159-2165.2004","article-title":"Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.","volume":"48","author":"Grossman","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-12-20210202","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/00002030-200404090-00008","article-title":"Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C.","volume":"18","author":"Grossman","year":"2004","journal-title":"AIDS"},{"key":"R13-12-20210202","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/nar\/29.1.296","article-title":"Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs.","volume":"29","author":"Kantor","year":"2001","journal-title":"Nucleic Acids Res"},{"key":"R14-12-20210202","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1128\/JVI.77.8.4836-4847.2003","article-title":"Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments.","volume":"77","author":"Wu","year":"2003","journal-title":"J Virol"},{"key":"R15-12-20210202","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","article-title":"A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.","volume":"44","author":"Petropoulos","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-12-20210202","doi-asserted-by":"crossref","first-page":"F9","DOI":"10.1097\/01.aids.0000232228.88511.0b","article-title":"HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.","volume":"20","author":"Brenner","year":"2006","journal-title":"AIDS"},{"key":"R17-12-20210202","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/00002030-200208160-00017","article-title":"M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.","volume":"16","author":"Ait-Khaled","year":"2002","journal-title":"AIDS"},{"key":"R18-12-20210202","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/135965350200700106","article-title":"Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.","volume":"7","author":"Ait-Khaled","year":"2002","journal-title":"Antiviral Ther"},{"key":"R19-12-20210202","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/135965350300800205","article-title":"HIV-1 reverse transcriptase and protease resistance mutations selected during 16\u201372 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir\/efavirenz\/amprenavir in the CNA2007 study.","volume":"8","author":"Ait-Khaled","year":"2003","journal-title":"Antiviral Ther"},{"key":"R20-12-20210202","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/135965350300800107","article-title":"Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation.","volume":"8","author":"Zaccarelli","year":"2003","journal-title":"Antiviral Ther"},{"key":"R21-12-20210202","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/infdis\/171.6.1411","article-title":"Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).","volume":"171","author":"Schuurman","year":"1995","journal-title":"J Infect Dis"},{"key":"R22-12-20210202","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1128\/JVI.74.8.3579-3585.2000","article-title":"The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis.","volume":"74","author":"Gotte","year":"2000","journal-title":"J Virol"},{"key":"R23-12-20210202","doi-asserted-by":"crossref","first-page":"13471","DOI":"10.1073\/pnas.95.23.13471","article-title":"Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism.","volume":"95","author":"Meyer","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R24-12-20210202","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1097-2765(00)80185-9","article-title":"A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase.","volume":"4","author":"Meyer","year":"1999","journal-title":"Mol Cell"},{"key":"R25-12-20210202","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1128\/AAC.37.10.2231","article-title":"High-level resistance to (-) enantiomeric 2\u2032-deoxy-3\u2032-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase.","volume":"37","author":"Boucher","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"R26-12-20210202","doi-asserted-by":"crossref","first-page":"5653","DOI":"10.1073\/pnas.90.12.5653","article-title":"Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3\u2032-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.","volume":"90","author":"Tisdale","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R27-12-20210202","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1126\/science.7542804","article-title":"Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.","volume":"269","author":"Larder","year":"1995","journal-title":"Science"},{"key":"R28-12-20210202","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1086\/315334","article-title":"Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection.","volume":"181","author":"Deeks","year":"2000","journal-title":"J Infect Dis"},{"key":"R29-12-20210202","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1128\/JCM.41.7.3007-3012.2003","article-title":"High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis.","volume":"41","author":"Nicastri","year":"2003","journal-title":"J Clin Microbiol"},{"key":"R30-12-20210202","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1097\/01.aids.0000131355.44834.e4","article-title":"Phenotypic impact of HIV reverse transcriptase M184I\/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.","volume":"18","author":"Ross","year":"2004","journal-title":"AIDS"},{"key":"R31-12-20210202","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1086\/426592","article-title":"Drug-resistant HIV infection among drug-naive patients in Israel.","volume":"40","author":"Grossman","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R32-12-20210202","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1086\/377742","article-title":"Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients.","volume":"188","author":"Winters","year":"2003","journal-title":"J Infect Dis"},{"key":"R34-12-20210202","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1128\/AAC.47.2.747-754.2003","article-title":"Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation.","volume":"47","author":"Quan","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"R35-12-20210202","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/01.aids.0000218542.08845.b2","article-title":"Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: A randomized pilot study (E-184V study).","volume":"20","author":"Castagna","year":"2006","journal-title":"AIDS"},{"key":"R36-12-20210202","first-page":"31","article-title":"Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients.","volume":"27","author":"Turner","year":"2004","journal-title":"New Microbiol"},{"key":"R37-12-20210202","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1586\/14787210.2.1.147","article-title":"The impact of the M184V substitution on drug resistance and viral fitness.","volume":"2","author":"Wainberg","year":"2004","journal-title":"Exp Rev Anti Infect Ther"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006454-200611000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:00:38Z","timestamp":1786028438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006454-200611000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.inf.0000243211.36690.d5","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}